GSK focuses ofatumumab development on subcutaneous delivery
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is to refocus the development of Genmab's ofatumumab in autoimmune indications on subcutaneous delivery and stop development in an intravenous route of administration.